By Josh Beckerman
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
The drug was approved for treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart-failure visits.
Cantor Fitzgerald wrote that "The most important thing is that it's approved with a broad label: by this, we mean mortality language is in fact included on the front page" and that the language about urgent heart failure visits is a differentiator compared with other products.
Amvuttra was previously approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 20, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。